Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093931 | 0.95 | ALDH1A1 (0.33) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3429421 | 0.90 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL29481369 | 0.83 | ALDH1A1 (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3092738 | 0.78 | ALDH1A1 (0.37) | ALDH1A1PYCR1 | |
| SCHEMBL16922402 | 0.77 | LMNA (0.50) | ALDH1A1TSHR | |
| SCHEMBL9753489 | 0.76 | CA12 (0.38) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3429259 | 0.75 | — | — | |
| SCHEMBL3429418 | 0.75 | CA12 (0.30) | CA12CA1CA2CA4CA9 | |
| SCHEMBL22082551 | 0.74 | CA12 (0.38) | CA12CA1CA2CA4CA9 | |
| SCHEMBL64992 | 0.74 | CYP1A2 (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903973-B1 | NEW AZIDES, METHODS FOR PRODUCING SAME AND APPLICATIONS THEREOF | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-06-28 | — | — | EP | disclosed |
| US-20150274701-A1 | NEW AZIDES, METHOD FOR PRODUCING SAME AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2903973-A1 | NEW AZIDES, METHODS FOR PRODUCING SAME AND APPLICATIONS THEREOF | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014057201-A1 | NEW AZIDES, METHODS FOR PRODUCING SAME AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274701-A1 | NEW AZIDES, METHOD FOR PRODUCING SAME AND APPLICATIONS THEREOF | SOD1, DUOX1, DUOX2 | CA12 634/4885CA1 388/4885CA2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.